Kien Trung Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kien Trung Nguyen has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
Lieu Thi Nguyen
8 shared publicationsVladislav Běhal
7 shared publicationsBlaise Lippa
Cubist Pharmaceuticals Inc., 65 Hayden Avenue, Lexington, MA 02421, USA
5 shared publicationsPaul Brian
Cubist Pharmaceuticals, Inc., Lexington, Massachusetts 02421
5 shared publicationsRichard H. Baltz
5 shared publicationsAnu Daniel
Cubist Pharmaceuticals, Inc. , 65 Hayden Avenue, Lexington, Massachusetts 02421, United States
4 shared publications
Latest Publications
- 1 April 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (8) , 1670-1680
Structure-based discovery of LpxC inhibitors
- 1 April 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (8) , 1670-1680
Structure-based discovery of LpxC inhibitors
- 16 February 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (4) , 374-378
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design
The ATPase subunit of DNA gyrase B is an attractive antibacterial target due to high conservation across bacteria and the essential role it plays in DNA replication. A novel class of pyrazolopyridone inhibitors was discovered by optimizing a fragment screening hit scaffold using structure guided design. These inhibitors show potent Gram-positive antibacterial activity and low resistance incidence against clinically important pathogens.
- 16 February 2016
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 7 (4) , 374-378
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design
The ATPase subunit of DNA gyrase B is an attractive antibacterial target due to high conservation across bacteria and the essential role it plays in DNA replication. A novel class of pyrazolopyridone inhibitors was discovered by optimizing a fragment screening hit scaffold using structure guided design. These inhibitors show potent Gram-positive antibacterial activity and low resistance incidence against clinically important pathogens.
- 1 February 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (4) , 1314-1318
Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB
- 1 February 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (4) , 1314-1318
Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB
- 22 October 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (21) , 8503-8512
Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors
The emergence and spread of multidrug resistant bacteria are widely believed to endanger human health. New drug targets and lead compounds exempt from cross-resistance with existing drugs are urgently needed. We report on the discovery of azaindole ureas as a novel class of bacterial gyrase B inhibitors and detail the story of their evolution from a de novo design hit based on structure-based drug design. These inhibitors show potent minimum inhibitory concentrations against fluoroquinolone resistant MRSA and other Gram-positive bacteria.
- 22 October 2015
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 58 (21) , 8503-8512
Discovery of Azaindole Ureas as a Novel Class of Bacterial Gyrase B Inhibitors
The emergence and spread of multidrug resistant bacteria are widely believed to endanger human health. New drug targets and lead compounds exempt from cross-resistance with existing drugs are urgently needed. We report on the discovery of azaindole ureas as a novel class of bacterial gyrase B inhibitors and detail the story of their evolution from a de novo design hit based on structure-based drug design. These inhibitors show potent minimum inhibitory concentrations against fluoroquinolone resistant MRSA and other Gram-positive bacteria.
- 14 September 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 6 (10) , 1080-1085
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors
Antibacterials with a novel mechanism of action offer a great opportunity to combat widespread antimicrobial resistance. Bacterial DNA Gyrase is a clinically validated target. Through physiochemical property optimization of a pyrazolopyridone hit, a novel class of GyrB inhibitors were discovered. Guided by structure-based drug design, indazole derivatives with excellent enzymatic and antibacterial activity as well as great animal efficacy were discovered.
- 14 September 2015
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 6 (10) , 1080-1085
Discovery of Indazole Derivatives as a Novel Class of Bacterial Gyrase B Inhibitors
Antibacterials with a novel mechanism of action offer a great opportunity to combat widespread antimicrobial resistance. Bacterial DNA Gyrase is a clinically validated target. Through physiochemical property optimization of a pyrazolopyridone hit, a novel class of GyrB inhibitors were discovered. Guided by structure-based drug design, indazole derivatives with excellent enzymatic and antibacterial activity as well as great animal efficacy were discovered.
- 30 April 2014
- Published by American Society for Microbiology
- p. 391-410
Genetic Engineering of Acidic Lipopeptide Antibiotics
- 30 April 2014
- Published by American Society for Microbiology
- p. 391-410
Genetic Engineering of Acidic Lipopeptide Antibiotics
- Open Access
- 20 April 2011
- Published by Oxford University Press (OUP) in FEMS Microbiology Letters
- Vol. 319 (2) , 176-179
Evaluating the activity of the RNA polymerase inhibitor myxopyronin B against Staphylococcus aureus
- 20 April 2011
- Published by Oxford University Press (OUP) in FEMS Microbiology Letters
- Vol. 319 (2) , 176-179
Open AccessEvaluating the activity of the RNA polymerase inhibitor myxopyronin B against Staphylococcus aureus
- 13 September 2010
- Published by Wiley
- p. 285-308
Reprogramming Daptomycin and A54145 Biosynthesis to Produce Novel Lipopeptide Antibiotics
- 13 September 2010
- Published by Wiley
- p. 285-308
Reprogramming Daptomycin and A54145 Biosynthesis to Produce Novel Lipopeptide Antibiotics
- 1 April 2010
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (4) , 1404-1413
Genetically Engineered Lipopeptide Antibiotics Related to A54145 and Daptomycin with Improved Properties
Daptomycin is a cyclic lipopeptide antibiotic approved for the treatment of skin and skin structure infections caused by Gram-positive pathogens and for that of bacteremia and right-sided endocarditis caused by Staphylococcus aureus . Daptomycin failed to meet noninferiority criteria for the treatment of community-acquired pneumonia, likely due to sequestration in pulmonary surfactant. Many analogues of daptomycin have been generated by combinatorial biosynthesis, but only two displayed improved activity in the presence of bovine surfactant, and neither was as active as daptomycin in vitro . In the present study, we generated hybrid molecules of the structurally related lipopeptide A54145 in Streptomyces fradiae and tested them for antibacterial activity in the presence of bovine surfactant. Hybrid A54145 nonribosomal peptide synthetase (NRPS) biosynthetic genes were constructed by genetic engineering and were expressed in combination with a deletion of the lptI methyltransferase gene, which is involved in the formation of the 3-methyl-glutamic acid (3mGlu) residue at position 12. Some of the compounds were very active against S. aureus and other Gram-positive pathogens; one compound was also highly active in the presence of bovine surfactant, had low acute toxicity, and showed some efficacy against Streptococcus pneumoniae in a mouse model of pulmonary infection.
- 1 April 2010
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (4) , 1404-1413
Genetically Engineered Lipopeptide Antibiotics Related to A54145 and Daptomycin with Improved Properties
Daptomycin is a cyclic lipopeptide antibiotic approved for the treatment of skin and skin structure infections caused by Gram-positive pathogens and for that of bacteremia and right-sided endocarditis caused by Staphylococcus aureus . Daptomycin failed to meet noninferiority criteria for the treatment of community-acquired pneumonia, likely due to sequestration in pulmonary surfactant. Many analogues of daptomycin have been generated by combinatorial biosynthesis, but only two displayed improved activity in the presence of bovine surfactant, and neither was as active as daptomycin in vitro . In the present study, we generated hybrid molecules of the structurally related lipopeptide A54145 in Streptomyces fradiae and tested them for antibacterial activity in the presence of bovine surfactant. Hybrid A54145 nonribosomal peptide synthetase (NRPS) biosynthetic genes were constructed by genetic engineering and were expressed in combination with a deletion of the lptI methyltransferase gene, which is involved in the formation of the 3-methyl-glutamic acid (3mGlu) residue at position 12. Some of the compounds were very active against S. aureus and other Gram-positive pathogens; one compound was also highly active in the presence of bovine surfactant, had low acute toxicity, and showed some efficacy against Streptococcus pneumoniae in a mouse model of pulmonary infection.